Phage Lytic Enzyme Cpl-1 as a Novel Antimicrobial for Pneumococcal Bacteremia

Streptococcus pneumoniae is becoming increasingly antibiotic resistant worldwide, and thus new antimicrobials are badly needed. We report the use of Cpl-1, the lytic enzyme of a pneumococcal bacteriophage, as an intravenous therapy for pneumococcal bacteremia in a mouse model. A 2,000-μg dose of Cpl...

Descripción completa

Detalles Bibliográficos

Publicado en:	Infect Immun
Autores principales:	Loeffler, Jutta M., Djurkovic, Svetolik, Fischetti, Vincent A.
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology (ASM) 2003
Materias:	Bacterial Infections
Acceso en línea:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC219578/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/14573637/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/IAI.71.11.6199-6204.2003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!